Cannabinoids for the Treatment of Schizophrenia: An Overview

Author(s): Anna Capasso, Eduardo Sobarzo-Sánchez, Seyed Fazel Nabavi, Luca Rastrelli

Journal Name: Current Topics in Medicinal Chemistry

Volume 16 , Issue 17 , 2016

Become EABM
Become Reviewer

Graphical Abstract:


Cannabinoids are found to be very useful in psychiatry because of their antipsychotic properties suggesting a therapeutic use as neuroleptic agents in limiting psychotic diseases. Cannabinoids treatments are both able to reduce the typical symptoms of schizophrenia and to slow down the disease aggravation. In the present review, we reported recent studies supporting the idea that the cannabinoid system may modulate the activity of the striatum and temporal cortex linked to psychosis and schizophrenia. Furthermore, anatomical, electrophysiological, pharmacological and biochemical data suggest that the psychotic disorders related to the impaired cannabinoid system may lead to the development of novel compounds that selectively target specific elements of the cannabinoid system.

Keywords: Antipsychotics, Cannabis sativa, Cannabinoids, Cannabidiol, THC, Natural products, Schizophrenia.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2016
Published on: 29 April, 2016
Page: [1916 - 1923]
Pages: 8
DOI: 10.2174/1568026616666160204122033
Price: $65

Article Metrics

PDF: 42
PRC: 2